Alopecia Management
Management of alopecia must be tailored to the specific type (alopecia areata vs androgenetic alopecia vs scarring alopecia), with treatment decisions prioritizing psychological impact and avoiding hazardous therapies for a condition that does not directly threaten physical health.
Critical Management Principle
The overriding consideration is that alopecia has no direct impact on general health that justifies hazardous treatments, particularly those of unproven efficacy 1. However, the psychological effects can significantly impact quality of life and must be addressed seriously 1.
Alopecia Areata Management
Disease Severity Stratification
Severity assessment now extends beyond simple scalp involvement percentage:
- Mild-to-moderate disease: SALT score <50 (less than 50% scalp hair loss)
- Severe disease: SALT ≥50 (50% or more scalp hair loss)
- Additional factors: Eyebrow/eyelash involvement, psychosocial impairment, and rate of disease progression should influence treatment decisions 2, 3
Treatment Algorithm by Severity
For Mild-to-Moderate AA (SALT <50):
- First-line: Intralesional corticosteroids or topical corticosteroids 2
- Adjunctive therapy: Topical or oral minoxidil 2
- Observation: May be appropriate in select cases given spontaneous remission occurs in 34-50% within 1 year, and 80% with small circumscribed patches 1
For Severe AA (SALT ≥50):
- First-line: Oral JAK inhibitors are now FDA-approved and represent the standard of care 2
- Selection among JAK inhibitors depends on patient age, comorbidities, laboratory monitoring requirements, and insurance coverage 2
- Important: Switching between JAK inhibitors may still benefit patients who don't respond to one agent 2
- Monitoring required: Due to immune suppression risks 4
Alternative/Adjunctive Therapies:
- Topical immunotherapy
- Systemic immunosuppressants (after failed systemic corticosteroids in Spain) 5
- Platelet-rich plasma
- Laser and light-based therapies
- Microneedling 2
Prognostic Counseling
Disease severity at presentation is the strongest predictor of long-term outcome 1:
- Patients with <25% hair loss initially: 68% disease-free at long-term follow-up
- Patients with 25-50% hair loss initially: 32% disease-free
- Patients with >50% hair loss initially: Only 8% disease-free 1
- 14-25% progress to alopecia totalis/universalis, from which full recovery is unusual (<10%) 1
Androgenetic Alopecia Management
First-line treatment is topical minoxidil 6. This is the most common form of alopecia and is typically genetic 6.
For male patients:
- Oral finasteride is an additional first-line option 6
- Oral dutasteride is another prescription option 7
For female patients:
- Antiandrogens like spironolactone 4
Emerging evidence: Oral minoxidil, platelet-rich plasma, fractionated lasers, and hair transplantation show efficacy, supporting a multifaceted approach 7.
Scarring Alopecias
Management includes:
- Systemic agents: Hydroxychloroquine and corticosteroids 4
- Adjunctive therapies: Topical and laser therapies 4
- Evidence limitation: Large data sets are lacking due to rarity, making evidence-based guidelines less robust than for non-scarring alopecias 8
Diagnostic Considerations
When Diagnosis is Uncertain
Appropriate tests include 1:
- Fungal culture (for tinea capitis)
- Skin biopsy (for scarring alopecia)
- Serology for lupus erythematosus
- Serology for syphilis
Routine Screening NOT Recommended
- Autoimmune disease screening: Insufficient justification despite increased frequency in AA patients 1
- Iron status testing: Not recommended; no published studies demonstrate treatment response to iron replacement 1
Dermoscopy Aids Diagnosis
Key findings in alopecia areata 1:
- Regular round yellow dots (indicate active disease progression)
- Exclamation mark hairs (dystrophic hairs with fractured tips)
- Cadaverized hairs (fractured before scalp emergence)
Differential Diagnosis Pitfalls
Trichotillomania causes the most diagnostic confusion 1:
- Distinguishing features: Incomplete hair loss pattern and broken hairs remain firmly anchored in anagen phase (unlike exclamation mark hairs in AA)
Other considerations: Tinea capitis (subtle scalp inflammation), early scarring alopecia, telogen effluvium, drug-induced anagen effluvium, systemic lupus erythematosus, secondary syphilis 1.
Psychological Management
Address the psychological burden directly 1:
- Patients commonly feel self-conscious, conspicuous, angry, rejected, or embarrassed
- They may behave in a shy, cautious, aggressive, retreating, evasive, or defensive (SCARED) manner
- Self-acceptance is crucial, particularly for long-standing, extensive, and persistent disease
- Patients with moderate-to-severe hair loss have higher rates of anxiety, depression, and lower work productivity 6
Setting Realistic Expectations
Counsel patients early about 8:
- Potential for hair regrowth with treatment
- Management is often lengthy (months to years)
- Hair follicles are preserved in alopecia areata; potential for recovery exists even in longstanding disease 1
- Hair care practices, personal care products, vitamins, and hairstyling device use